Connect with us

Technology

RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO

Published

on

STOCKHOLM, May 3, 2025 /PRNewswire/ — At this week’s ESTRO conference in Vienna, RaySearch Laboratories AB (publ) and Vision RT proudly announces the next step in their collaboration: the full integration of MapRT with RayStation®* treatment planning system. This integration enables full access to the MapRT clearance map in RayStation to guide the user during treatment planning in choosing beam trajectories clear from collisions between the treatment unit, patient and couch.

During CT simulation, MapRT cameras capture the entire surface of the patient, along with any immobilization accessories. The MapRT software then analyzes this data, alongside models of the treatment couch and machine, to identify safe gantry and couch angles which are represented by a clearance map that is immediately accessible in RayStation.

The integration is designed to optimize beam options for better plans and minimize the need for dry runs. This is particularly important for treatment plans where the couch is rotated. Recent studies have demonstrated that non-coplanar treatments can significantly improve treatment plans for several cancers, including lung1,2,3,4, breast5,6,7,8, head and neck cancers9,10,11,12,13, lymphoma14,15, and high-grade glioma16. These treatments can offer clinically relevant benefits, such as improved organ-at-risk dose sparing.

Helen Convery, Senior Dosimetrist (Development & Clinical Trials), who has tested the integration, says: “We have used MapRT at Raigmore Hospital since 2022 and have found it invaluable for checking for collision on all plans and optimizing non-coplanar plan angles. I think the integration into RayStation is of significant value and I can see it further streamlining and improving the efficiency of our workflow.”

Thomas Carter, VP of Marketing, Vision RT, adds: “We are already seeing clinics changing their planning techniques, allowing their patients to benefit from the extra beam options MapRT provides. This integration has the potential to streamline workflows, reduce errors, and free up resources, all while improving treatment predictability. It also opens the path for automated, collision-free planning.”

Björn Hårdemark, Deputy CEO, RaySearch: “Surface scanning is an excellent source of information about the most central aspect of radiation therapy – the patient. The tight integration between MapRT and RayStation makes this information available already during treatment planning, allowing the user to explore more creative beam configurations while maintaining clearance around the patient. It is a great example of how clinical benefit can be achieved through collaboration between radiation therapy technology vendors.”

MapRT is approved for CE marking and clinical distribution in the EU and UK. A version without the API is currently cleared for sale in the USA, with API version 510(k) pending.

About Vision RT
Vision RT is the inventor of Surface Guided Radiation Therapy (SGRT) which uses camera systems to track surface data, to offer more guidance across every step of the radiotherapy workflow: simulation, planning, treatment and dose visualization. We work tirelessly to improve the accuracy, efficiency, safety and comfort of radiation therapy.

Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 21,000 people.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch’s software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.

* Subject to regulatory clearance in some markets.

For more information, please contact: 

Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00 
johan.lof@raysearchlabs.com  

Learn more about us on:
LinkedIn
YouTube

[1] Ma M, Ren W, Li M, Niu C, Dai J. Dosimetric comparison of coplanar and non-coplanar beam arrangements for radiotherapy of patients with lung cancer: A meta-analysis. J Appl Clin Med Phys. 2021 Apr;22(4):34-43. doi: 10.1002/acm2.13197. Epub 2021 Feb 26. PMID: 33634946; PMCID: PMC8035566.

[2] Kim ST, An HJ, Kim JI, Yoo JR, Kim HJ, Park JM. Non-coplanar VMAT plans for lung SABR to reduce dose to the heart: a planning study. Br J Radiol. 2020 Jan;93(1105):20190596. doi: 10.1259/bjr.20190596. Epub 2019 Oct 22. PMID: 31625759; PMCID: PMC6948076.

[3] Lincoln JD, MacDonald RL, Syme A, Thomas CG. Static couch non-coplanar arc selection optimization for lung SBRT treatment planning. Phys Med Biol. 2023 Jul 21;68(15). doi: 10.1088/1361-6560/ace23f. PMID: 37369237.

[4]Chapet O, Khodri M, Jalade P, N’guyen D, Flandin I, D’hombres A, Romestaing P, Mornex F. Potential benefits of using non-coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. Radiother Oncol. 2006 Sep;80(3):333-40. doi: 10.1016/j.radonc.2006.07.009. Epub 2006 Aug 24. PMID: 16934354.

[5] J, F., et al. (2023). Locoregional breast radiotherapy including IMN: optimizing the dose distribution using an automated non-coplanar VMAT-technique. Acta oncologica (Stockholm, Sweden), [online] 62(10). doi:https://doi.org/10.1080/0284186X.2023.2264488.

[6] Xu, Y., Ma, P., Hu, Z., Tian, Y., Men, K., Wang, S., Xu, Y. and Dai, J. (2021). Non-coplanar volumetric modulated arc therapy for locoregional radiotherapy of left-sided breast cancer including internal mammary nodes. Radiology and Oncology, 55(4), pp.499–507. doi:https://doi.org/10.2478/raon-2021-0045.

[7] A, B., et al. (2023). Dosimetric Comparision of Coplanar versus Non-coplanar Volumetric Modulated Arc Therapy for Treatment of Bilateral Breast Cancers. Journal of medical physics, [online] 48(3). doi:https://doi.org/10.4103/jmp.jmp_36_23.

[8] Biau J, Lopez L, Thivat E, Casile M, Millardet C, Saroul N, Pham-Dang N, Molnar I, Bourhis J, Lapeyre M. Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial. Clin Transl Radiat Oncol. 2022 Nov 14;38:169-174. doi: 10.1016/j.ctro.2022.11.07. PMID: 36466746; PMCID: PMC9712819.

[9]Woods KE, Ma TM, Cook KA, Morris ED, Gao Y, Sheng K, Kishan AU, Hegde JV, Felix C, Basehart V, Narahara K, Shen Z, Tenn S, Steinberg ML, Chin RK, Cao M. A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes. Cancers (Basel). 2022 Feb 14;14(4):939. doi: 10.3390/cancers14040939. PMID: 35205686; PMCID: PMC8870161.

[10] Gayen S, Kombathula SH, Manna S, Varshney S, Pareek P. Dosimetric comparison of coplanar and non-coplanar volumetric-modulated arc therapy in head and neck cancer treated with radiotherapy. Radiat Oncol J. 2020 Jun;38(2):138-147. doi: 10.3857/roj.2020.00143. Epub 2020 May 26. PMID: 33012157; PMCID: PMC7533406.

[11] Gayen S, Kombathula SH, Manna S, Varshney S, Pareek P. Dosimetric comparison of coplanar and non-coplanar volumetric-modulated arc therapy in head and neck cancer treated with radiotherapy. Radiat Oncol J. 2020 Jun;38(2):138-147. doi: 10.3857/roj.2020.00143. Epub 2020 May 26. PMID: 33012157; PMCID: PMC7533406.

[12] Subramanian VS, Subramani V, Chilukuri S, Kathirvel M, Arun G, Swamy ST, Subramanian K, Fogliata A, Cozzi L. Multi-isocentric 4π volumetric-modulated arc therapy approach for head and neck cancer. J Appl Clin Med Phys. 2017 Sep;18(5):293-300. doi: 10.1002/acm2.12164. Epub 2017 Aug 20. PMID: 28834021; PMCID: PMC5874945.

[13] Wild, E., Bangert, M., Nill, S. and Oelfke, U. (2015). Non-coplanar VMAT for nasopharyngeal tumors: Plan quality versus treatment time. Medical Physics, 42(5), pp.2157–2168. doi:https://doi.org/10.1118/1.4914863.

[14] Rossi L, Cambraia Lopes P, Marques Leitão J, Janus C, van de Pol M, Breedveld S, Penninkhof J, Heijmen BJM. On the Importance of Individualized, Non-Coplanar Beam Configurations in Mediastinal Lymphoma Radiotherapy, Optimized With Automated Planning. Front Oncol. 2021 Apr 15;11:619929. doi: 10.3389/fonc.2021.619929. PMID: 33937025; PMCID: PMC8082440.

[15]  Chen X, Jin D, Wang S, Li M, Huang P, Dai J. Non-coplanar intensity-modulated radiation therapy for young female patients with mediastinal lymphoma. J Appl Clin Med Phys. 2012 Nov 8;13(6):3769. doi: 10.1120/jacmp.v13i6.3769. PMID: 23149772; PMCID: PMC5718536.

[16] Yu VY, Landers A, Woods K, Nguyen D, Cao M, Du D, Chin RK, Sheng K, Kaprealian TB. A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients. Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):144-151. doi: 10.1016/j.ijrobp.2018.01.048. Epub 2018 Jan 31. PMID: 29619962.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/raysearch-laboratories-and-vision-rt-present-innovations-in-surface-guided-treatment-planning-at-est,c4144768

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-and-vision-rt-present-innovations-in-surface-guided-treatment-planning-at-estro-302445457.html

SOURCE RaySearch Laboratories

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

THE MINISTRY OF DEFENCE ENHANCES NATIONAL RESILIENCE THROUGH SMART DEFENCE TECHNOLOGY INNOVATION

Published

on

By

KUALA LUMPUR, Malaysia, April 22, 2026 /PRNewswire/ — On April 20, The Prime Minister of Malaysia, YAB Dato’ Seri Anwar bin Ibrahim, officiated the Defence Services Asia (DSA) & National Security (NATSEC) Asia 2026 Opening Ceremony at the Malaysia International Trade and Exhibition Centre (MITEC).

Themed “Enhancing Capabilities and Resilience Through Technology”, the 19th Edition of the DSA 2026 Exhibition will run for four days from 20 to 23 April 2026. This exhibition aims to enhance defence capabilities and drive future technology to ensure national resilience through innovation, international cooperation and the development of the local defence industry ecosystem.

The main focus of this event is on the evolution of defence technology that has shifted from conventional assets to smart systems. Emphasis is placed on mastering technology that is capable of facing the security threats of the new millennium which are asymmetric and hybrid in nature.

Among the core advanced technologies featured :

a) Autonomous & Robotic Systems: Exhibition of various variations of unmanned systems (UAV, UGV, and UUV) equipped with Artificial Intelligence (AI) for long-distance monitoring and detection operations.

b) Digital & Cyber Defence: Application of new generation encryption technology and cybersecurity platforms to protect the country’s data sovereignty and critical infrastructure.

c) Sensor & Electronic Technology: High-precision radar and sensor systems that enable ATM readiness to be at an optimal level in monitoring space, maritime, and land in real-time.

In line with this global technology exposure, the government continues to strengthen the Industrial Collaboration Programme (ICP) as the main mechanism for technology transfer. Through the ICP, the involvement of international industry players is required to contribute to the development of local talent and research and development (R&D) in the high-tech sector.

Among the key segments highlighted are the CBRNe Arena, focusing on technologies related to chemical, biological, radiological, nuclear and explosive threats; the Firearms and Tactical Equipment Segment, showcasing the latest operational capabilities and equipment; and the Coalition of Defence Industry Malaysia (CDIM) Pavilion, which highlights the capabilities of the country’s defence industry. The DSA & NATSEC Asia Lab also showcases innovation initiatives by providing a platform for small and medium-sized enterprises (SMEs) and start-ups to introduce their innovations on the international stage.

This edition recorded the participation of 1,456 companies from 63 countries, including 37 international pavilions, as well as approximately 600 official delegations and 50,000 trade visitors from more than 114 countries within the 48,000-square-metre exhibition space. This scale of participation reflects the strategic importance of the exhibition at the global level and further demonstrates Malaysia’s position as a strategic meeting point for defence and security cooperation.

Also present were the Minister of Defence, YB Dato’ Seri Mohamed Khaled Nordin; Chief Secretary to the Government, Tan Sri Shamsul Azri Abu Bakar; Speaker of the Dewan Rakyat, Tan Sri Dato’ Dr. Johari bin Abdul; Chairman of DSA Exhibition and Conference Sdn Bhd, Tan Sri Asmat Kamaludin; Chief of Defence Force, General Datuk Haji Malek Razak bin Sulaiman; Secretary-General of the Ministry of Defence, Datuk Lokman Hakim bin Ali; Deputy Minister of Defence, YB Adly Zahari; as well as top management and senior officers of the Ministry and the Malaysian Armed Forces.

– END –

“‘MALAYSIA MADANI” “BERKHIDMAT UNTUK NEGARA”
”PERTAHANAN NEGARA, TANGGUNGJAWAB BERSAMA”

Ministry of Defence Malaysia
20 April 2026

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/the-ministry-of-defence-enhances-national-resilience-through-smart-defence-technology-innovation-302749464.html

SOURCE DSA & NATSEC ASIA

Continue Reading

Technology

Grantd Launches Platform to Help Employees Understand Their Equity, Build Confidence in Their Financial Plan, and Connect to Advice When They Need It

Published

on

By

New Platform Gives Every Equity Recipient a Personalized View of Their Awards — and a Clear Path to Understand, Act, and Get Advice on Them

DENVER, April 21, 2026 /PRNewswire-PRWeb/ — Grantd, an AI-powered equity compensation platform whose advisor platform helps advisors manage over $14 billion in assets under administration for more than 400 registered investment advisory firms and 14,000 clients, today announced the launch of its issuer platform, Grantd for Work. The platform is built to give employees a clear, personalized understanding of their equity compensation — what they have, what it’s worth, how it fits into their broader financial picture, and what they should consider doing about it. Equity compensation is complex, and for most employees, it has been difficult to navigate without dedicated resources and support. Grantd for Work changes that — providing the tools, education, and guidance employees need to understand their awards with confidence, and connecting them to a financial advisor when they’re ready to take the next step.

“It gives every employee a real, personalized view of their equity — what it means for their financial goals, what actions they should consider, and a direct line to advice when they need it.”

The launch marks a significant expansion of Grantd’s reach — from individual equity recipients and their financial advisors to the employers and employees inside the companies that grant those awards. It also helps HR and compensation administrators gain better visibility into their programs, reduce the volume of manual employee questions, and identify where engagement and retention may be at risk.

“Equity is one of the most powerful forms of compensation companies offer — but for most employees, it’s also one of the least understood,” said Brian McDonald, Founder & CEO of Grantd. “An employee might receive an RSU grant, watch it vest, and still have no idea what the tax implications are, whether they should sell or hold, or how it changes their financial picture. Grantd for Work changes that. It gives every employee a real, personalized view of their equity — what it means for their financial goals, what actions they should consider, and a direct line to advice when they need it.”

Grantd for Work is built around the employee experience. Key capabilities include:

A personalized equity dashboard showing each employee’s total portfolio value, vested and unvested equity broken down by grant, external holdings, and concentration risk — giving them a complete, real-time picture of what they own, what it’s worth, and how it fits into their overall financial picture.AI-powered document reading that automatically extracts holdings from any brokerage statement or equity award summary — from any provider — so the platform is accurate and fully populated from day one, with no manual entry required.Financial goal tracking that maps each employee’s equity directly to their personal financial goals — financial independence, early retirement, a home purchase — showing whether they’re on track, what’s at risk, and how upcoming vests and exercises could change the outcome.A full equity planning toolkit, including concentration analysis, price target modeling, growth scenario projections, exercise planning, withholding analysis, and trading window tracking — alongside pre-built strategy templates like sell-to-cover, diversification sell-down, and automated trading plans.Ask Grant, an AI equity guide built directly into the platform that answers employees’ most pressing questions — from how RSU income is taxed at vest to what the ESPP 15% discount means for their tax situation — in plain language, on demand.AI agents that work for every employee — Grantd’s AI agents don’t wait to be asked. They continuously analyze each employee’s equity portfolio and surface timely, personalized insights. Every insight is specific to that employee — not generic equity education, but guidance grounded in what they actually hold.A learning center with articles and guides covering equity basics, tax and finance, investing strategy, and company-specific plan guides — so employees can build real confidence in their equity, not just access to it.A direct connection to financial advice when employees are ready to go beyond self-service — with their complete equity profile already structured and ready to share with an advisor.

For HR and compensation administrators, the platform also provides visibility into how equity programs are performing across the organization — including a live dashboard of total equity wealth created by employee, department, and level; proactive retention signals for employees with expiring grants or low engagement; and competitive equity modeling tools to help design compelling offers for prospective hires.

The new platform arrives at a time when industry leaders are rethinking equity program design and employee share plan strategy. Grantd will further that conversation at the Global Equity Organization’s (GEO) 27th Annual Conference in Austin, taking place April 21–23, 2026. On Wednesday, April 22, Brian McDonald will join the expert panel, “Strategic Shifts in Employee Share Plans: How Companies Are Redesigning Equity for 2026 and Beyond,” alongside fellow Grantd Advisory Board members Billy Vitense of Starbucks, Christine Zwerling of Asana, and Melissa Howell of Nike.

To learn more about Grantd for Work or schedule a demonstration, visit Grantd online at https://www.grantdequity.com/.

About Grantd:

Founded by Brian McDonald, Grantd is an AI-powered equity compensation platform built to simplify how equity is understood, managed, and acted on. Its advisor platform manages over $14 billion in assets under administration for more than 400 registered investment advisory firms, 2,600 advisors, and 14,000 clients. With the launch of Grantd for Work, the company now serves the full equity ecosystem — from individual equity recipients and their advisors to the employees who hold those awards and the HR and compensation teams who design and run the programs. Grantd is headquartered in Denver, Colorado.

Media Contact

Jane Kim, Grantd Equity, 1 (303) 515-3158, jane.kim@grantdequity.com, grantdequity.com

View original content:https://www.prweb.com/releases/grantd-launches-platform-to-help-employees-understand-their-equity-build-confidence-in-their-financial-plan-and-connect-to-advice-when-they-need-it-302745530.html

SOURCE Grantd Equity

Continue Reading

Technology

FERMI PROVIDES BUSINESS UPDATE

Published

on

By

DALLAS, April 21, 2026 /PRNewswire/ — Fermi Inc. (d/b/a Fermi America) (NASDAQ: FRMI) (LSE: FRMI), operating as Fermi America™ (“Fermi” or the “Company”), subsequent to the Company’s announcement of Fermi 2.0 on April 20, 2026, has received significant and positive feedback from multiple potential tenants, the Company’s landlord, the Texas Tech University System, as well as suppliers, vendors, contractors, financing sources, and other partners. The Company is gratified by that feedback and is pursuing Fermi 2.0’s business and leadership objectives with all deliberate speed.

The Company also acknowledges receipt of a letter from Mr. Toby Neugebauer, and has reviewed a press release issued by him, calling for the initiation of a process for the immediate sale of the Company. As Mr. Neugebauer indicated in his press release, he was removed from his position on April, 17, 2026,  after careful consideration by the Company’s Board of Directors in accordance with its fiduciary duties. Given recent changes in leadership, which position the Company for its next chapter of growth and evolution from a startup to a scaled enterprise, the Company firmly believes a sale is not in the best interest of its continued momentum on Project Matador, ability to serve potential tenants and long-term value creation for shareholders. The Board, consistent with its fiduciary duties, will carefully review all avenues to maximize shareholder value, which include continued execution of its business plan, strategic investments from third parties, joint ventures or other transactions.

About Fermi America™

Fermi America™ (NASDAQ & LSE: FRMI) (fermiamerica.com) is pioneering the development of next-generation private electric grids that deliver highly redundant power at gigawatt scale, required to create next-generation artificial intelligence. Co-founded by former U.S. Energy Secretary Rick Perry and Co-Founder and former Co-Managing Partner of Quantum Energy Toby Neugebauer, Fermi America™ combines cutting-edge technology with a deep bench of proven world-class multi-disciplinary leaders to create the world’s largest, 17 GW next-generation private HyperGrid campus. Project Matador is expected to integrate the nation’s biggest combined-cycle natural gas project, one of the largest clean, new nuclear power complexes in America, utility grid power, solar power, and battery energy storage, to deliver hyperscaler artificial intelligence.

Additional Information and Where to Find It

If the Company determines to hold a special meeting of shareholders, the Company will file a proxy statement on Schedule 14A, an accompanying white proxy card and other relevant documents with the Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies from the Company’s shareholders for such meeting. SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), IF ANY, AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders may obtain a copy of any definitive proxy statement of the Company, an accompanying white proxy card, any amendments or supplements thereto and other documents filed by the Company with the SEC if and when they become available at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge in the “SEC Filings” subsection of the Company’s Investor Relations website at https://fermiamerica.com/ or by contacting the Company’s Investor Relations Department at IR@fermiamerica.com, as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.

Participants in the Solicitation

If the Company determines to hold a special meeting of shareholders, the Company, its directors and certain of its executive officers may be deemed participants in the solicitation of proxies from the Company’s shareholders in connection with matters to be considered at such special meeting of shareholders. Information regarding the direct and indirect interests, by security holdings or otherwise, of the Company’s directors and executive officers is included in the Company’s final prospectus, filed with the SEC on October 1, 2025, the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and in the Company’s Current Reports on Form 8-K filed with the SEC from time to time. Changes to the direct or indirect interests of the Company’s directors and executive officers are set forth in SEC filings on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4. These documents are available free of charge as described above. Updated information regarding the identities of potential participants and their direct or indirect interests, by security holdings or otherwise, in the Company will be set forth in the definitive proxy statement for the Company’s special meeting of shareholders and other relevant documents to be filed with the SEC, if and when they become available.

Forward-Looking Statements

Statements contained in this press release which are not historical facts, such as those relating to future events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Fermi undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Investors should consult further disclosures and risk factors included in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-8 and other documents filed from time to time with the SEC by Fermi.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fermi-provides-business-update-302749474.html

SOURCE Fermi Inc.

Continue Reading

Trending